Uses of IL-13 antagonists for treating atopic dermatitis
Uses of IL-13 antagonists for treating atopic dermatitis are provided. Also provided are methods of treating atopic dermatitis and methods of reducing the severity of atopic dermatitis by administering IL-13 antagonists.
1 . A method of treating atopic dermatitis in a patient, the method comprising administering to the patient an IL-13 antibody, wherein administering comprises administering a loading dose of 250 mg or 500 mg of the anti-IL-13 antibody and administering a subsequent maintenance dose of 125 mg of the anti-IL-13 antibody, wherein the loading dose is administered once or twice, and the maintenance dose is administered for the remainder of treatment duration, wherein the anti-IL-13 antibody is an antibody comprising a heavy chain having the amino acid sequence of SEQ ID NO: 11 and a light chain having the amino acid sequence of SEQ ID NO: 12, wherein the administration of the anti-IL-13 antibody reduces disease severity in the patient, and wherein the disease severity is assessed by an Atopic Dermatitis Disease Severity Outcome Measure.
2 . The method of claim 1 , wherein the maintenance dose is administered four weeks after administration of the loading dose, and once every four weeks thereafter for the treatment duration.
3 . The method of claim 1 , wherein the treatment duration is 24 weeks or more.
4 . The method of claim 3 , wherein the treatment duration is 24 weeks.
5 . The method of claim 1 , wherein the Atopic Dermatitis Disease Severity Outcome Measure is Eczema Area and Severity Index (EASI).
6 . The method of claim 1 , wherein the Atopic Dermatitis Disease Severity Outcome Measure is Severity Scoring of Atopic Dermatitis (SCORAD).
7 . The method of claim 1 , wherein the Atopic Dermatitis Disease Severity Outcome Measure is Investigator Global Assessment (IGA).
8 . The method of claim 1 , wherein the Atopic Dermatitis Disease Severity Outcome Measure is a Patient Reported Outcome (PRO).
9 . The method of claim 8 , wherein the PRO is pruritus visual analogue scale (VAS), sleep loss VAS, or Atopic Dermatitis Impact Questionnaire (ADIQ) score.
10 . The method of claim 1 , wherein the atopic dermatitis is moderate to severe as determined by Rajka/Langeland criteria score and wherein the Rajka/Langeland criteria score is determined to be between 4.5 and 9.
11 . The method of claim 1 , wherein the IL-13 antibody is administered subcutaneously to the patient using a subcutaneous administration device.
12 . The method of claim 11 , wherein the subcutaneous administration device is selected from a prefilled syringe, disposable pen injection device, microneedle device, microinfuser device, needle-free injection device, and autoinjector device.
13 . The method of claim 1 , wherein the method further comprises administration of one or more topical corticosteroids.
14 . The method of claim 13 , wherein the one or more topical corticosteroids is or are administered before, concurrent with, or after administration of the IL-13 antibody.
15 . The method of claim 14 , wherein the one or more topical corticosteroids is or are selected from triamcinolone acetonide, hydrocortisone, and a combination of triamcinolone acetonide and hydrocortisone.
16 . The method of claim 1 , wherein the patient is 12 years of age or older.
17 . The method of claim 1 , wherein the patient's atopic dermatitis is inadequately controlled by topical corticosteroids.